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Executive Summary:  
This study researched the birth control patch, Ortho Evra and the diffusivity of the 
hormones, ethinyl estradiol and norelogestromin, into the body through the epidermis.  
We modeled that all of the species that diffused through the epidermis was completely 
absorbed into the body.  We found that our model validated the amounts given by Ortho 
Evra for drug release.  However, many of the constraints and boundary conditions were 
taken from the Ortho Evra research information.  Our study also analyzed the 
effectiveness of the hormone in women of varying weight, from 120 pounds to 198 
pounds.  Results indicated that the patch becomes less and less effective with increasing 
adipose tissue.  This increase in adipose tissue results in a decreasing diffusivity value for 
the epidermis.  Our study also researched the effects of incorrect usage of the Ortho Evra 
patch.  We modeled the scenario of the patch falling off after a given time and the 
continued effectiveness of the drug.  Our values imply that if the patch falls off the 
woman is not protected.  The woman must restart the cycle in-order to reach steady state, 
which provides the needed amount of drug to be effective. 
Introduction: 
Our study will explore the mass transfer effects of a birth control patch.  The patch is  
very helpful and has become popular in the world of birth control because it allows the 
user to have constant protection without a daily pill.  This helps prevent one of the major 
disadvantages of the pill – forgetting to take it.  The patch can be placed on multiple parts 
of the skin and the drugs are then transferred to the blood stream from which they flow 
throughout the body.  The manufacturing company has listed four specific spots to put 
the patch because of effective drug diffusivity values for those areas: the buttocks, the 
abdomen, the upper arm, and the upper torso.  This study focuses on the only current 
company that produces a birth control patch, Ortho Evra.  The dimensions of the area 
studied will be approximately the area of the patch, with a small area of skin surrounding 
it.  We will have to construct a tissue layer for the body parts we use and find properties 
for skin, the drug, and patch   
In tests it has been found that Ortho Evra is effective in 99 out of 100 women who use the 
product for the entire year, similar to that of the pill.  In the 15 pregnancies found in the 
study of 3330 women, 5 of the women had a weight greater than 198 pounds.  This was 
found to be statistically significant by the studies.  We will model the difference in a 
woman of 125 pounds against that of a 200-pound individual.  The difference will be 
monitored by adjusting adipose tissue levels in the skin, thus altering diffusivity values. 
Design Objectives: 
The goal of our project is to study the drug delivery form Ortho Evra into the 
bloodstream.  We would like to look at what happens in women of varying weight as 
described in our Introduction.   
We also wanted to test other problems with incorrect use.  Since the patch is placed in 
four different areas of the body that can be high friction, we wanted to simulate what 
would happen if the patch fell off after a certain amount of time and whether a woman 
would still be protected. 
Geometry, Boundary Conditions 
We are modeling the diffusion of norelgestromin and ethinyl estradiol from the patch, 
through the skin and into the blood.  We are modeling the square patch as a circle so that 
we may use axi-symmetric properties to simplify the problem in FIDAP.  To get the same 
area, we approximate the radius of the circular patch to be 2.53 cm.  We are also 
modeling the patch with .5 cm of skin around it to include diffusive spreading out from 
the edge of the patch.  We used .5 cm instead of 1 cm because the skin is so thin that the 
drugs can’t diffuse out very far before they have diffused into the blood. 
 
 
 
 
 
                                               Figure 1. Schematic of our Patch and Skin Area. 
 As a result, our mesh is almost the same as during preliminary testing.  We have 
reduced the size of the radius from 3.5 cm to 3 cm.  Also, we have changed the interval 
sizes.  There are now many more nodes closer to the patch than the blood in order to 
better capture the diffusion of the drug into the skin.  See Fig 2. (attached) for a picture of 
the mesh. 
 For the solution, we are using the initial blood concentration of norelgestromin as 
7 x 10-4 g/m3 and the initial flux at the patch – skin boundary as 8.849 x 10-7 g/m2s.  The 
diffusivity of the skin layer is 5.55 x 10-12 m2/s.  The diffusivity of skin has been obtained 
from speaking with two dermatogists: Michael Saltzman, and Dr. Richard Guy.  The 
initial flux from the patch for ethinyl estradiol is 1.1789 x 10-7 g/m2s.   These figures 
were used in FIDAP to obtain the following information displayed in Figures 3 and 4. 
The main problem we had in obtaining these solutions was with our dimensions.  After 
changing our problem to non-dimensionalized terms we were able to obtain a proper 
solution.  Our next section will explain how we non-dimensionalized the terms. 
Non-Dimensionalizing our Problem:
Because FIDAP had trouble calculating a solution with such a small diffusivity, we 
decided to non-dimensionalize our mesh and governing equation. We divided the 
dimensions of the mesh by 1.2e-3 meters, which is the actual length of the axis. This set 
the axis to a unit length of 1, but we also had to alter our equations for the time step and 
flux. Diffusivity is then set to 1 in FIDAP.  
 
Original dimensions for mesh 
Axis: 1.2 e-3 meters 
Skin (including patch length): 3 e-2 meters 
Patch length only: 2.5 e-2 meters 
 
Non-dimensional mesh dimensions: 
Axis: 1 
Skin: 25 
Patch: 20.8333 
 
Time 
Time = D*Normal Time / L^2 
Where normal time for an hour would be 3600 seconds, L = 1.2 e-3 m, D = diffusivity, 
1.11 x 10-12 m2/s 
 
Flux 
Flux = Normal flux * L / D 
Where normal flux = 8.849 x 10-7 g/m2s (norelgestromin value), L = 1.2 e-3 m, D = 
diffusivity, 1.11 x 10-12 m2/s 
 
Results and Discussion 
Qualitative Description of What is Happening:
When looking at Figure 2 the drug is being delivered from the bottom 4/5 of the mesh 
from left to right.  Some of the drug also diffuses upwards because of diffusion in all 
directions.  In a three-dimensional sense our mesh is rotated along the bottom to create 
the schematic shown in Figure 1.   
Since the dermis layer contains the dermal papillae we decided that would be the easiest 
place to model the drug delivery.  This is why we have made the assumption of no dermal 
layer, only an epidermal layer.  Once the drug reaches the blood it is completely washed 
away.  Therefore we have no reaction term, and no half-life term.   
Computational Results: 
We ran the solution in FIDAP and obtained the contours for norelogestromin and ethinyl 
estradiol shown in Figures 3 and 4. We then obtained the plot shown in Figure 9 of the 
norelgestromin concentration at node 273, which shows that the system reaches steady 
state after two days. However, we need to determine if enough of the species was 
reaching the bloodstream over the course of a day after the system had reached steady 
state. To do this, we determined the flux over the capillary-epidermis boundary using 
FIDAP for several time intervals over the course of one day. We then utilized the 
trapezoid rule to calculate how much of the drug had reached the bloodstream. Our 
calculations showed that 149.722 micrograms of norelogestromin diffused into the blood 
while 2.004 micrograms of ethinyl estradiol diffused into the blood. While the 
concentration for norelgestromin was incredibly accurate when compared to the Ortho 
Evra literature, the concentration for ethinyl estradiol was off by a factor of 10. The 
reason for this error is because we optimized the diffusivity value only for norelgestromin 
and not for ethinyl estradiol. 
Mesh Convergence:
In order to show that our solution was independent of the mesh we created a refined mesh 
(Figure 5).  Our original mesh had 400 nodes and was graded near the patch/skin 
boundary.  In our new mesh we used 10,000 nodes.  As shown by comparing the contour 
plots in Figures 3 and 6 we have similar values, proving that our solution was 
independent of the mesh created. 
Sensitivity Analysis: 
As stated in our introduction we wanted to look at a couple different scenarios when 
working with the birth control patch.   
Women of Varying Weight:
For our sensitivity analysis we tried using different diffusivity values to test how our 
results changed.  After speaking with our dermatologists, Dr. Guy explained that in 
women with increased weight there is an increase in the amount of adipose tissue.  This 
causes the diffusivity value to decrease and it can do so up to 100-fold.  For our study we 
modeled diffusivity values decreased by 10-fold and 100-fold.  From the chart below one 
can see how the value changed the amount of the drug being delivered to the drug stream.   
 
Diffusivity Constant (in ) Amount of Drug Reaching the Bloodstream 
over 24 hours at Steady State 
Original Value 149.7 micrograms 
10 times smaller 45 micrograms 
100 times smaller .04 micrograms 
 
The differences in values above can be explained by Figure 7.  As seen in the figure the 
drug builds up near the surface and does not diffuse across the skin fast enough.  
Therefore the effective amount of the drug is not being delivered to the body.  (Note: 
These Values are For Norelogestromin Only) 
Patch Falling Off 
For our second sensitivity analysis we wanted to model what would happen if the patch 
fell off and whether the woman would still be protected . In order to do this we used the 
Time Function command in FIDAP.  After a specified amount of time (as shown in the 
table below) we set our flux condition to 0 at the patch/skin interface.  Figure 8 shows 
how the amount of drug being delivered changed at a specific node over time. 
Time when Patch Falls Off (in days) Amount of Drug Delivered in the 
Following 24 hours 
3 Days 86 micrograms 
2 Days 18 micrograms 
1 Day 4 micrograms 
 
As shown during the study with women of varying weight again the effective drug levels 
needed to keep the women protected will not be maintained if the patch falls off. (Note: 
These values are for Norelgestromin Only) 
Conclusion and Design Recommendations:
In looking at the realistic constraints for our project we thought that four of them were 
important to discuss to the consumer: Economic, Sustainability, Health and Safety, and 
Social. 
Economic – The patch is relatively inexpensive, about $15/patch.  In order to make a 
more effective patch for larger women we would need to somehow change the diffusivity 
of the skin, which seemed to be the problem.  Perhaps finding a smaller drug that could 
penetrate easier.   
Sustainability – the patch is obviously a one time use, and it is not suggested to be used if 
it falls off.  The adhesion between the patch and skin is obviously very important for 
proper drug delivery. 
Health and Safety – there are very few health risks associated with the patch.  Most are 
the same from the pill.  Girls will still have their menstrual cycles, etc.  Some women 
experienced breast symptoms, headache, application site reaction, nausea, upper 
respiratory infection, menstrual cramps and abdominal pain.  People who smoke also are 
prone to have additional cardiovascular side effects.  The patch has been found 
ineffective in women of larger weight (over 198 pounds).   
Social – the patch provides some social benefits such that the woman does not have to 
worry about taking the pill on a certain time regime, she is able to put aside her worries 
since the patch is working.  On the other hand, the woman has a patch on her skin in 
some pretty visible areas at times.  For the woman who has trouble remembering, or finds 
it inconvenient to take the pill out of her purse or pocket the patch is beneficial.    
In order to create an effective birth control patch for women with increased adipose 
tissue, it might be necessary to design a larger patch. Our sensitivity analysis did not 
include varying the size of the patch, but this could easily be incorporated into a future 
study. Also, the increased adipose tissue would result in a thicker mesh. This analysis is a 
cost-effective way in determining whether the Ortho Evra patch is an effective means of 
birth control for overweight women. It remains to be seen how much the cost will go up 
if the patch size is increased or a different drug is used in the patch. Using FIDAP to 
estimate whether these modifications are effective is a cost-saving measure, as it will 
decrease the costs for experimental testing of said modifications. 
APPENDIX A: Mathematical Statement of the Problem 
Governing Equation: 
 
 
 
 
Species equation 
• CD = concentration of drug 
• t  = time 
• x = distance 
• DD = diffusivity constant 
 
 
 
 
 
 
 Mesh Schematic 
                                         Figure 1A. 
Boundary Conditions 
For norelgestromin, we calculated the flux at the patch-skin boundary to be 8.849 x 10-7 
g/m2. For ethinyl estradiol, the initial flux is 1.1789 x 10-7 g/m2s. 
Initial Condition 
C = 0 at t = 0 for all x 
Diffusivity 
Using information from several scientific journal articles, we decided on a diffusion 
coefficient of 5.55 x 10  m /s, but that is for water.  Our material is much larger of a 
molecule than water so it would diffuse slower.  After speaking with Dr. Guy we have 
decided that our material would diffuse about 10 times as slowly.  So we will use a 
coefficient of 5.55 x 10  m /s.   
-11 2
-12 2
From a similar study it was found that in skin tissue filled with lipids, the value would be 
much smaller.  Therefore for a lipid-filled tissue, the diffusion would be 5.55 x 10-14 m2/s. 
After using these values in FIDAP, the solution did not reach steady state in two days.  
Therefore, we used a trial-and-error strategy to determine the diffusivity so that the 
system would reach steady state in two days. Our final value for the diffusivity was set at 
1.11 x 10-11 m2/s. 
Input Parameters 
Parameter Value
Diffusivity 1.11 x 10-11 m2/s 
Norelgestromin flux 8.849 x 10-7 g/m2
Ethinyl Estradiol flux 1.1789 x 10-7 g/m2s 
Epidermis Thickness 1.2 x 10-3 m 
Patch radius 0.25 m 
APPENDIX B 
Problem Command: 
 
PROB (AXI-, INCO, TRAN, LAMI, LINE, NEWT, NOMO, ISOT, FIXE, NOST, 
NORE, SING, SPEC = 1.0) 
 
Our problem approximated a square patch as a circular patch with the same area so we 
could use an axisymmetric geometry. Everything used in the model incompressible and 
Newtonian. The problem is transient, but we are attempting to find when it reaches steady 
state.  Though there are no fluid flows, if there were, they would be laminar.  This means 
that there is no momentum as well.  The problem did not consider any sort of heat 
transfer so it was isothermal without any convection.  The project was also designed so 
that the structural solver and remeshing would be unnecessary.  Also, there was no phase 
change.  We only modeled one species at a time. 
 
Execution Command: 
 
EXEC (NEWJ) 
 
This command tells FIDAP that it is working on a new problem so that it will not inherit 
anything from other problems that could be ongoing. 
 
Solution Command: 
 
SOLU (S.S. = 10, ACCF = 0.000000000000E+00) 
 
This command tells FIDAP to use successive substitutions for each time step.  It can use 
a maximum of 10 iterations for each solution. 
 
Time Integration Command: 
 
TIME (BACK, NSTE = 10000, TSTA = 0.000000000000E+00, TEND = 4.662, 
       DT = 0.100000000000E-01, VARI = 0.1, WIND, NOFI, INCM = 10.0) 
 
This command shows FIDAP that there will be 10000 time steps with the following start 
and end times.  The times are unusual numbers because they have been non-
dimensionalized. 
 
Entity Commands: 
 
ENTI (NAME = "TISSUE", SOLI) 
 ENTI (NAME = "AXIS", PLOT) 
 ENTI (NAME = "SIDELOW", PLOT) 
 ENTI (NAME = "SIDETOP", PLOT) 
 ENTI (NAME = "TOP", PLOT) 
 ENTI (NAME = "skin", PLOT) 
 ENTI (NAME = "PATCH", PLOT) 
 
This tells FIDAP each of the separate entities that are being used for this problem.  Only 
the “TISSUE” entity is specified as a solid material because the other entities are 
boundaries.  The “TISSUE” is the material in which the species will diffuse through. 
 
Diffusivity:
 
DIFF (SET = 1, CONS = 1.0) 
 
The diffusivity property has been non-dimensionalized to get over FIDAP’s problem with 
very small diffusivity constants.  The other constants are changed around the diffusivity 
in order to keep it at 1. 
 
Boundary Nodes: 
 
BCNO (SPEC = 1.0, ENTI = "SIDELOW", CONS = 0.000000000000E+00) 
 BCNO (SPEC = 1.0, ENTI = "SIDETOP", CONS = 0.000000000000E+00) 
 
This was to ensure that the concentration at the initial time step for the side of the mesh 
without the patch was fixed at a constant concentration of zero. 
 
Boundary Flux: 
 
BCFL (SPEC = 1.0, ENTI = "PATCH", CONS = 95.665) 
 
This sets the flux to come from the patch with a concentration that has been non-
dimensionalized. 
 
Initial Condition: 
 
ICNO (SPEC = 1.0, ZERO, ENTI = "TISSUE") 
 
Our initial condition assumed that the skin layer had none of the species in it before the 
patch was placed on the skin.  Any species in the skin later would have to be the result of 
diffusion from the patch. 
 
 
 
 
 
 
ATTACHMENTS 
Figure 2. Unrefined Mesh  
 
 
 
 
 
 
 
 
 
 
Figure 3.  Norelgestromin Plot                                     Figure 4. Ethinyl Estradiol Plot 
 
 
 
 
 
 
 
 
 
Figure 2 
Figure 5. Refined Mesh with 10000 nodes            Figure 6. Refined Mesh Plot for 
       Norelgestromin    
          
 
 
 
 
 Figure 7. Diffusivity Constant for women of 198 lbs    Figure 8. Concentration vs. Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9: Plot of Norelgestromin Concentration at Node 273 over one week 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 10: Original Mesh with Node Numbers 
 
Figure 11: Location of Node 273 in Mesh 
Figure 13: Sample Flux Plot Over Sidelow 
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